Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

CellsforLife: cell micro-encapsulation based localized chemotherapy for treating pancreatic cancer

Reference number
Coordinator Kungliga Tekniska Högskolan - KTH Avdelningen för Mikro och nanosystem
Funding from Vinnova SEK 1 918 522
Project duration June 2019 - June 2023
Status Completed

Important results from the project

In our research, we have explored novel medicine: tiny "capsules" that can house living cells. The capsules are like protective bubbles for cells made from a mix of special gel and spider silk. These capsules might be future mini-factories for cancer drugs. We´ve seen the cells inside stay healthy for a week, and the spider silk provides a sturdy, friendly shield against immune reactions. This could revolutionize treatments, making therapies more targeted and effective.

Expected long term effects

In our research, we´ve developed microcapsules using a blend of gel and spider silk, specifically designed for pancreatic cancer treatment. These capsules house kidney cells and have shown potential in producing targeted chemotherapy drugs. The innovative use of spider silk ensures the cells remain intact and functional. Preliminary results indicate these capsules are effective, especially in their localized drug production. By further analyzing their impact on tumors, we aim to enhance the precision and efficiency of cancer treatments.

Approach and implementation

**Setup and Implementation - Analysis:** We studied cell encapsulation for therapeutic uses. Our method combines a sodium alginate hydrogel with a thin spider silk shell. The process: 1) Encapsulate modified kidney cells in hydrogel threads. 2) Slice threads and wrap in spider silk. Results showed cells remain viable inside the capsules, hinting at targeted chemotherapy potential. The spider silk ensures efficient molecule transport and protects cells from immune responses.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 22 August 2023

Reference number 2019-02182